146 related articles for article (PubMed ID: 18460822)
1. Species difference in the contribution of T-type calcium current to cardiac pacemaking as revealed by r(-)-efonidipine.
Tanaka H; Komikado C; Namekata I; Nakamura H; Suzuki M; Tsuneoka Y; Shigenobu K; Takahara A
J Pharmacol Sci; 2008 May; 107(1):99-102. PubMed ID: 18460822
[TBL] [Abstract][Full Text] [Related]
2. The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium.
Tanaka H; Komikado C; Shimada H; Takeda K; Namekata I; Kawanishi T; Shigenobu K
J Pharmacol Sci; 2004 Dec; 96(4):499-501. PubMed ID: 15599089
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect.
Masumiya H; Shijuku T; Tanaka H; Shigenobu K
Eur J Pharmacol; 1998 May; 349(2-3):351-7. PubMed ID: 9671117
[TBL] [Abstract][Full Text] [Related]
4. Effects of S(+)-efonidipine on the rabbit sinus node action potential and calcium channel subunits Ca(V)1.2, Ca(V)1.3 and Ca(V)3.1.
Tanaka H; Namekata I; Ogawa T; Tsuneoka Y; Komikado C; Takahara A; Iida-Tanaka N; Izumi-Nakaseko H; Tsuru H; Adachi-Akahane S
Eur J Pharmacol; 2010 Dec; 649(1-3):263-7. PubMed ID: 20858482
[TBL] [Abstract][Full Text] [Related]
5. Effects of Ca2+ channel antagonists on sinus node: prolongation of late phase 4 depolarization by efonidipine.
Masumiya H; Tanaka H; Shigenobu K
Eur J Pharmacol; 1997 Sep; 335(1):15-21. PubMed ID: 9371541
[TBL] [Abstract][Full Text] [Related]
6. Possible requirement of phosphonate moiety for efonidipine effects on the sino-atrial node action potential.
Masumiya H; Matsuda T; Tanaka Y; Tanaka H; Shigenobu K
Life Sci; 2000; 66(16):PL239-44. PubMed ID: 10794505
[TBL] [Abstract][Full Text] [Related]
7. Frequency-dependent blockade of T-type Ca2+ current by efonidipine in cardiomyocytes.
Masumiya H; Kase J; Tanaka Y; Tanaka H; Shigenobu K
Life Sci; 2000 Dec; 68(3):345-51. PubMed ID: 11191650
[TBL] [Abstract][Full Text] [Related]
8. A selective T-type Ca2+ channel blocker R(-) efonidipine.
Shin MC; Kim CJ; Min BI; Ogawa S; Tanaka E; Akaike N
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):411-21. PubMed ID: 18278483
[TBL] [Abstract][Full Text] [Related]
9. T-type Ca2+ channel blockade prevents sudden death in mice with heart failure.
Kinoshita H; Kuwahara K; Takano M; Arai Y; Kuwabara Y; Yasuno S; Nakagawa Y; Nakanishi M; Harada M; Fujiwara M; Murakami M; Ueshima K; Nakao K
Circulation; 2009 Sep; 120(9):743-52. PubMed ID: 19687356
[TBL] [Abstract][Full Text] [Related]
10. Effect of cilnidipine on L- and T-type calcium currents in guinea pig ventricle and action potential in rabbit sinoatrial node.
Takeda K; Yamagishi R; Masumiya H; Tanaka H; Shigenobu K
J Pharmacol Sci; 2004 Jul; 95(3):398-401. PubMed ID: 15272218
[TBL] [Abstract][Full Text] [Related]
11. Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels.
Tanaka H; Shigenobu K
Cardiovasc Drug Rev; 2002; 20(1):81-92. PubMed ID: 12070536
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of the dual L- and T-type Ca2+ channel blocker efonidipine on cardiomyopathic hamsters.
Suzuki S; Ohkusa T; Ono K; Sato T; Yoshida MA; Yano M; Takebayashi S; Matsuzaki M
Circ J; 2007 Dec; 71(12):1970-6. PubMed ID: 18037756
[TBL] [Abstract][Full Text] [Related]
13. Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels.
Furukawa T; Miura R; Honda M; Kamiya N; Mori Y; Takeshita S; Isshiki T; Nukada T
Br J Pharmacol; 2004 Dec; 143(8):1050-7. PubMed ID: 15545287
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular selectivity of 1,4-dihydropyridine derivatives, efonidipine (NZ-105), nicardipine and structure related compounds in isolated guinea-pig tissues.
Masuda Y; Miyajima M; Shudo C; Tanaka S; Shigenobu K; Kasuya Y
Gen Pharmacol; 1995 Mar; 26(2):339-45. PubMed ID: 7590084
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of T-type and L-type Ca(2+) currents by aranidipine, a novel dihydropyridine Ca(2+) antagonist.
Masumiya H; Tanaka Y; Tanaka H; Shigenobu K
Pharmacology; 2000 Aug; 61(2):57-61. PubMed ID: 10940777
[TBL] [Abstract][Full Text] [Related]
16. Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.
Perez-Reyes E; Van Deusen AL; Vitko I
J Pharmacol Exp Ther; 2009 Feb; 328(2):621-7. PubMed ID: 18974361
[TBL] [Abstract][Full Text] [Related]
17. Effects of the iron chelator deferiprone and the T-type calcium channel blocker efonidipine on cardiac function and Ca
Khamseekaew J; Kumfu S; Palee S; Wongjaikam S; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
Cell Calcium; 2018 Jun; 72():18-25. PubMed ID: 29748130
[TBL] [Abstract][Full Text] [Related]
18. Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation.
Ohashi N; Mitamura H; Ogawa S
Drugs; 2009; 69(1):21-30. PubMed ID: 19192934
[TBL] [Abstract][Full Text] [Related]
19. Myocardial and vascular effects of efonidipine in vitro as compared with nifedipine, verapamil and diltiazem.
Tanaka H; Masumiya H; Sekine T; Sijuku T; Sugahara M; Taniguchi H; Terada M; Saito W; Shigenobu K
Gen Pharmacol; 1996 Apr; 27(3):451-4. PubMed ID: 8723524
[TBL] [Abstract][Full Text] [Related]
20. Effect of efonidipine on TGF-β1-induced cardiac fibrosis through Smad2-dependent pathway in rat cardiac fibroblasts.
Lei B; Hitomi H; Mori T; Nagai Y; Deguchi K; Mori H; Masaki T; Nakano D; Kobori H; Kitaura Y; Nishiyama A
J Pharmacol Sci; 2011; 117(2):98-105. PubMed ID: 21897055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
